Keyphrases
Anti-CD20 Antibody
100%
Xenograft
100%
Zirconium-89 (89Zr)
100%
Human Lymphoma
100%
Ofatumumab
88%
Obinutuzumab
77%
Tositumomab
66%
Rituximab
44%
Radioimmunotherapy
44%
Positron Emission Tomography-computed Tomography (PET-CT)
33%
Biodistribution
33%
Tumor Uptake
33%
Monoclonal Antibody
22%
B-cell Lymphoma
22%
After Injection
22%
CD20
22%
Redosing
22%
Tumor
11%
Effective Treatment
11%
B Lymphocytes
11%
U.S. Food
11%
Tumor Targeting
11%
Severe Combined Immunodeficient Mice
11%
Peptide Sequencing
11%
Human IgG
11%
Humanized
11%
Burkitt Lymphoma
11%
Murine Antibody
11%
Theranostics
11%
Small Animal PET
11%
Preclinical Animal Models
11%
Previous Generation
11%
Injected Dose
11%
Fully Human
11%
Raji
11%
Palpable Tumor
11%
Repeated Dosing
11%
Splenic Uptake
11%
89Zr-rituximab
11%
Medicine and Dentistry
Xenograft
100%
CD20 Antibody
100%
Zirconium 89
100%
Ofatumumab
88%
Obinutuzumab
77%
Neoplasm
66%
Rituximab
66%
Tositumomab
66%
Radioimmunotherapy
44%
Positron Emission Tomography-Computed Tomography
33%
Biodistribution
33%
B-Cell Lymphoma
22%
Monoclonal Antibody
22%
CD20
22%
SCID Mouse
11%
Peptide Sequence
11%
Burkitt's Lymphoma
11%
B Lymphocyte Antigen
11%
Immunology and Microbiology
Xenograft
100%
CD20 Antibody
100%
Ofatumumab
100%
Obinutuzumab
87%
Rituximab
75%
Tositumomab
75%
Monospecific Antibody
37%
Positron Emission Tomography-Computed Tomography
37%
Monoclonal Antibody
25%
B Cell
25%
CD20
25%
Mouse
12%
Mouse Model
12%
SCID Mouse
12%
Amino Acid Sequence
12%
Murine
12%
B Lymphocyte Antigen
12%
Pharmacology, Toxicology and Pharmaceutical Science
CD20 Antibody
100%
Zirconium 89
100%
Ofatumumab
88%
Obinutuzumab
77%
Neoplasm
66%
Rituximab
66%
Tositumomab
66%
Biodistribution
33%
B Cell Lymphoma
22%
Monoclonal Antibody
22%
Mouse
11%
Mouse Model
11%
SCID Mouse
11%
Murine
11%
Burkitt's Lymphoma
11%
B Lymphocyte Antigen
11%